NASDAQ:ACET Adicet Bio (ACET) Stock Forecast, Price & News $5.48 -0.13 (-2.32%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$5.40▼$5.7250-Day Range$5.27▼$7.1352-Week Range$5.13▼$21.87Volume785,671 shsAverage Volume478,014 shsMarket Capitalization$235.42 millionP/E RatioN/ADividend YieldN/APrice Target$27.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adicet Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside398.2% Upside$27.40 Price TargetShort InterestHealthy9.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.15Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.18) to ($2.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector489th out of 1,006 stocksPharmaceutical Preparations Industry236th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAdicet Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.40, Adicet Bio has a forecasted upside of 398.2% from its current price of $5.50.Amount of Analyst CoverageAdicet Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.77% of the float of Adicet Bio has been sold short.Short Interest Ratio / Days to CoverAdicet Bio has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Adicet Bio has recently decreased by 7.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdicet Bio does not currently pay a dividend.Dividend GrowthAdicet Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACET. Previous Next 2.9 News and Social Media Coverage News SentimentAdicet Bio has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adicet Bio this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adicet Bio insiders have not sold or bought any company stock.Percentage Held by Insiders29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adicet Bio are expected to decrease in the coming year, from ($2.18) to ($2.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adicet Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adicet Bio is -2.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdicet Bio has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adicet Bio (NASDAQ:ACET) StockAdicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf“ gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.Read More Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Stock News HeadlinesMay 30, 2023 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Short Interest UpdateMay 25, 2023 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 31, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 19, 2023 | americanbankingnews.comAdicet Bio (NASDAQ:ACET) Coverage Initiated at StockNews.comMay 18, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Adicet Bio (ACET)May 18, 2023 | msn.comAdicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical StudyMay 18, 2023 | finance.yahoo.comAdicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingMay 15, 2023 | msn.comJMP Securities Reiterates Adicet Bio (ACET) Market Outperform RecommendationMay 31, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 15, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Adicet Bio (ACET)May 14, 2023 | americanbankingnews.comShort Interest in Adicet Bio, Inc. (NASDAQ:ACET) Grows By 16.1%May 14, 2023 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) to Post FY2023 Earnings of ($3.38) Per Share, Wedbush ForecastsMay 14, 2023 | americanbankingnews.comAdicet Bio, Inc. to Post Q2 2023 Earnings of ($0.73) Per Share, HC Wainwright Forecasts (NASDAQ:ACET)May 13, 2023 | americanbankingnews.comFY2026 EPS Estimates for Adicet Bio, Inc. Decreased by Wedbush (NASDAQ:ACET)May 12, 2023 | msn.comWedbush Reiterates Adicet Bio (ACET) Outperform RecommendationMay 11, 2023 | msn.comHC Wainwright & Co. Maintains Adicet Bio (ACET) Buy RecommendationMay 10, 2023 | msn.comAdicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2023 | finance.yahoo.comAdicet Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 9, 2023 | finance.yahoo.comAdicet Bio to Present at the 2023 JMP Securities Life Sciences ConferenceMay 9, 2023 | americanbankingnews.comAdicet Bio (ACET) to Release Earnings on WednesdayMay 9, 2023 | americanbankingnews.comAdicet Bio (ACET) Scheduled to Post Quarterly Earnings on WednesdayApril 28, 2023 | americanbankingnews.comAnalysts Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $27.40April 17, 2023 | finance.yahoo.comAdicet Bio, Inc.'s (NASDAQ:ACET) Price Is Out Of Tune With RevenuesApril 13, 2023 | finance.yahoo.comAdicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 3, 2023 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Receives $27.50 Consensus Target Price from AnalystsMarch 21, 2023 | americanbankingnews.comAdicet Bio, Inc. (NASDAQ:ACET) Forecasted to Post Q1 2023 Earnings of ($0.70) Per ShareMarch 21, 2023 | americanbankingnews.comAdicet Bio, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.78) Per Share (NASDAQ:ACET)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACET Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ACET Company Calendar Last Earnings3/15/2023Today5/31/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryTrading Companies & Distributors SectorMedical Current SymbolNASDAQ:ACET CUSIP00444610 CIK2034 Webwww.aceto.com Phone(650) 503-9095FaxN/AEmployees86Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.40 High Stock Price Forecast$38.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+400.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,790,000.00 Net MarginsN/A Pretax Margin-279.27% Return on Equity-36.01% Return on Assets-31.91% Debt Debt-to-Equity RatioN/A Current Ratio12.98 Quick Ratio12.98 Sales & Book Value Annual Sales$24.99 million Price / Sales9.42 Cash FlowN/A Price / Cash FlowN/A Book Value$6.20 per share Price / Book0.88Miscellaneous Outstanding Shares42,960,000Free Float30,285,000Market Cap$235.42 million OptionableOptionable Beta2.20 Key ExecutivesChen SchorPresident, CEO, Secretary & DirectorBrian Nicholas HarveyChief Financial & Accounting OfficerFrancesco GalimiChief Medical Officer & Senior Vice PresidentDonald HealeyChief Technology OfficerBlake AftabChief Scientific Officer & Senior Vice PresidentKey CompetitorsLifecore BiomedicalNASDAQ:LFCRPMV PharmaceuticalsNASDAQ:PMVPThorne HealthTechNASDAQ:THRNTango TherapeuticsNASDAQ:TNGXRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 5,516 shares on 5/18/2023Ownership: 0.054%New York State Common Retirement FundSold 6,800 shares on 5/18/2023Ownership: 0.027%Geode Capital Management LLCBought 16,033 shares on 5/16/2023Ownership: 1.411%Balyasny Asset Management L.P.Bought 4,733 shares on 5/16/2023Ownership: 0.064%Susquehanna International Group LLPBought 10,900 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACET Stock - Frequently Asked Questions Should I buy or sell Adicet Bio stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACET shares. View ACET analyst ratings or view top-rated stocks. What is Adicet Bio's stock price forecast for 2023? 4 analysts have issued 12 month price targets for Adicet Bio's stock. Their ACET share price forecasts range from $19.00 to $38.00. On average, they predict the company's stock price to reach $27.40 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts. How have ACET shares performed in 2023? Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 38.7% and is now trading at $5.48. View the best growth stocks for 2023 here. Are investors shorting Adicet Bio? Adicet Bio saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,930,000 shares, a decline of 7.6% from the April 30th total of 3,170,000 shares. Based on an average trading volume of 471,600 shares, the short-interest ratio is presently 6.2 days. Approximately 9.8% of the shares of the stock are short sold. View Adicet Bio's Short Interest. When is Adicet Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ACET earnings forecast. How were Adicet Bio's earnings last quarter? Adicet Bio, Inc. (NASDAQ:ACET) posted its quarterly earnings data on Wednesday, March, 15th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.16. What ETFs hold Adicet Bio's stock? ETFs with the largest weight of Adicet Bio (NASDAQ:ACET) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Genomics Immunology and Healthcare ETF (IDNA) and Simplify Propel Opportunities ETF (SURI).iShares U.S. Tech Breakthrough Multisector ETF (TECB). What other stocks do shareholders of Adicet Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include Marin Software (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE). What is Adicet Bio's stock symbol? Adicet Bio trades on the NASDAQ under the ticker symbol "ACET." Who are Adicet Bio's major shareholders? Adicet Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.91%), Carlyle Group Inc. (4.92%), Geode Capital Management LLC (1.41%), State Street Corp (1.31%), Dimensional Fund Advisors LP (1.30%) and Wellington Management Group LLP (1.17%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Chen Schor, Don Healey, Francesco Galimi and Jay P Elliott. View institutional ownership trends. How do I buy shares of Adicet Bio? Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adicet Bio's stock price today? One share of ACET stock can currently be purchased for approximately $5.48. How much money does Adicet Bio make? Adicet Bio (NASDAQ:ACET) has a market capitalization of $235.42 million and generates $24.99 million in revenue each year. The company earns $-69,790,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. How can I contact Adicet Bio? Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The official website for the company is www.aceto.com. The company can be reached via phone at (650) 503-9095 or via email at jburfening@lhai.com. This page (NASDAQ:ACET) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adicet Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.